Figure 3 | Scientific Reports

Figure 3

From: Levodopa/benserazide microsphere (LBM) prevents L-dopa induced dyskinesia by inactivation of the DR1/PKA/P-tau pathway in 6-OHDA-lesioned Parkinson's rats

Figure 3

Time course of AIMs score development in 6-OHDA-lesioned rats during a 3 weeks treatment with L-dopa + benserazide, LBM-L (20 mg/kg), LBM-M (40 mg/kg) and LBM-H (60 mg/kg).

6-OHDA-lesioned rats treated with LBM did not develop LID over the 21 day treatment period, which differed significantly from the LID groups in all testing sessions. (A) sum of axial, limb and orolingual, (B) axial, (C) limb and (D) orolingual AIMs on each testing session were rated following the administration of LBM. Data are presented as mean ± standard error; # p < 0.01, ## p < 0.05 vs LID.

Back to article page